{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=9", "query": { "condition": "Gastric Adenocarcinomas", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 632, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:01:49.997Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02241720", "title": "Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Upper GI Cancer" ], "interventions": [ { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-05", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02241720" }, { "nct_id": "NCT04208958", "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Melanoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "VE800", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Vancomycin Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Vedanta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2020-01-23", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208958" }, { "nct_id": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Part A", "type": "BIOLOGICAL" }, { "name": "Part B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TopAlliance Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-02-21", "completion_date": "2022-07-07", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 14, "location_summary": "Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474640" }, { "nct_id": "NCT02443324", "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Adenocarcinoma", "Adenocarcinoma of the Gastroesophageal Junction", "Non-small Cell Lung Cancer", "Carcinoma, Transitional Cell", "Biliary Tract Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-07-29", "completion_date": "2022-04-12", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443324" }, { "nct_id": "NCT01253161", "title": "Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Carcinoid Tumors" ], "interventions": [ { "name": "Pasireotide Long Acting Release (LAR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2011-02-01", "completion_date": "2023-03-02", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 2, "location_summary": "Stanford, California • Tampa, Florida", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01253161" }, { "nct_id": "NCT03675737", "title": "Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "Placebo for Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1579, "start_date": "2018-11-08", "completion_date": "2025-03-03", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 10, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03675737" }, { "nct_id": "NCT00012363", "title": "S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2001-04", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 96, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012363" }, { "nct_id": "NCT04989387", "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Gastrointestinal (GI) Malignancies" ], "interventions": [ { "name": "INCA00186", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "INCB106385", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 57, "start_date": "2021-10-04", "completion_date": "2024-09-19", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 8, "location_summary": "Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04989387" }, { "nct_id": "NCT03092518", "title": "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophagogastric Junction", "Gastric Cancer" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Sodium Thiosulfate", "type": "DRUG" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "CT C/A/P", "type": "DIAGNOSTIC_TEST" }, { "name": "PET-CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-06-05", "completion_date": "2024-07-24", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03092518" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-14T16:01:49.997Z", "location_count": 18, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" } ] }